RxDoctor Payments Data

Jeannie Umanzor

Psychiatric/Mental Health · van Nuys, CANPI 1992234165

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $13,009 of the $17,058 with a category attached, or 76.3%. 13 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 56.4% of the total. 2025 is the largest year on record at $9,624, more than ten times the $279 reported in 2022. Among psychiatric/mental health clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$17,058in general payments, 2019–2025

Across 166 payments — averaging $102.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$10K
  • Otsuka America Pharmaceutical, Inc.$6K
  • Lundbeck LLC$577
  • Alkermes, Inc.$300
  • AbbVie$125
  • Viiv Healthcare Company$119
  • plus $353 from 7 others

What the payments were for

  • Speaking & faculty fees$13,00976%
  • Travel & lodging$9185%
  • Food & beverage$2,99818%
  • Education$1321%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,058 in reported general payments places this provider in the 95th percentile of 2,433 psychiatric/mental health providers in California.

See all psychiatric/mental health providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxazepam13$2,758
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl14$2,382
Bupropion Hcl13$330
Aripiprazole16$262
Mirtazapine13$213
Quetiapine Fumarate30$190
Bupropion XlBupropion Hcl16$174
Benztropine Mesylate15$112

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USABuprenorphine-Naloxone$57$2,38214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,433 psychiatric/mental health providers in California.

Other psychiatric/mental health in van Nuys

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →